logo
I Asked ChatGPT How To Invest Like a Rich Person: Here's What It Said

I Asked ChatGPT How To Invest Like a Rich Person: Here's What It Said

Yahoo2 days ago

Many folks are beginning to use ChatGPT instead of Google when looking for information. They're switching because ChatGPT is quicker and more specific. People are also using ChatGPT for financial assistance and even personal financial analysis. Is this a good idea? We wouldn't go that far but it can be a good starting point.
Find Out:
Read Next:
GOBankingRates put the generative AI chatbot to the test, asking how to invest like a rich person. Here's what ChatGPT said in response.
The first tip the chatbot shared is to think long term. This is really the only smart way to approach investing and is heavily recommended by the best investors, including Warren Buffett. ChatGPT posted the following points here.
Prioritize capital preservation and steady growth.
Embrace long-term investing horizons.
Let compound interest work for decades.
These are all astute points, but ChatGPT doesn't get deep with them. It should at least, however briefly, discuss what compound interest is, as that's the key benefit of a long-term investing strategy.
The Consumer Financial Protection Bureau defines compound interest as 'when you earn interest on the money you've saved and on the interest you earn along the way.' For a more human-sounding explanation, consider Buffett's analogy. He likens compound interest to a snowball rolling down a long hill, collecting more snow as it picks up speed, eventually becoming a massive snowball. Your investment is the snowball, and time is the hill.
Learn More:
Another salient tip from ChatGPT: Diversify strategically. Rich people swear by investing across numerous categories, including:
Stocks and bonds
Private equity and venture capital
Real estate
Alternative assets like crypto
This is all accurate, but there's more to strategic diversification. You should know the purpose of this and why it's important. Diversification reduces your risk should a stock (or the market at large) tank. Nothing eliminates risk in the investing world, but diversification is the tool to manage it.
Here's another principle that Buffett insists on implementing in your investment strategy. Invest in what you understand. Never buy stock solely because you hear it's hot right now or because you believe in the company behind it. The latter is important, but research is more important.
ChatGPT highlighted the following instructions.
Invest in sectors they know well (e.g., tech, real estate, private equity).
Do deep due diligence before investing.
But there's a bit more to this advice. Investing in what you know is not a one-time deal. Throughout your investment journey, you should be keeping in the know of what's happening behind the scenes of your investments. For example, if a company you're heavily backing is experiencing calamity in its leadership, be aware of that. This doesn't mean you should bail, but you do want to have your finger on the pulse, always.
Yes, ChatGPT, this is a really important point. If you want to invest like a rich person, you need to be taking full advantage of tax-advantaged accounts, including the following:
IRAs
401(k) plans
HSAs
Trusts
LLCs
Ultra-wealthy people usually own assets such as real estate or businesses that generate passive income. ChatGPT highlighted the importance of owning assets if you want to invest like a rich person.
ChatGPT instructed readers to be strategic with debt, saying, 'Use good debt to invest (e.g., mortgages, business loans); avoid high-interest consumer debt.'
The second point is nonnegotiable. Carrying high-interest debt is a major no-no no matter your desired wealth status. But the first part, about using 'good debt' to invest is controversial advice. We mustn't assume any mortgage or business loan debt is 'good.' All debt carries risk and can become 'bad,' so you need to work with a financial advisor to build a plan where debt works in your favor.
Right on time, ChatGPT provided this tip: 'Use financial planners, tax advisors, lawyers and estate planners,' the chatbot said. You 100% need to do this. We often read this as the last tip, but it probably should be the first one, if you really want to invest like a rich person.
More From GOBankingRates
Mark Cuban Tells Americans To Stock Up on Consumables as Trump's Tariffs Hit -- Here's What To Buy
This article originally appeared on GOBankingRates.com: I Asked ChatGPT How To Invest Like a Rich Person: Here's What It Said
Error in retrieving data
Sign in to access your portfolio
Error in retrieving data
Error in retrieving data
Error in retrieving data
Error in retrieving data

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Washington Post Probes Hack of Journalist Email Accounts
Washington Post Probes Hack of Journalist Email Accounts

Bloomberg

time38 minutes ago

  • Bloomberg

Washington Post Probes Hack of Journalist Email Accounts

By and Jane Lanhee Lee Save The Washington Post is investigating a cyber attack on the email accounts of some journalists, prompting the newspaper to beef up its online security. The intrusion was discovered late Thursday and the company carried out a forced reset of login credentials for all staff the following night, according to a memo sent by Executive Editor Matt Murray to affected employees on Sunday. The memo, reviewed by Bloomberg News, said the attack affected a limited number of email accounts of journalists and a forensic team had been brought in to investigate.

Gold Steady Near Record High as Mideast War Drives Haven Bids
Gold Steady Near Record High as Mideast War Drives Haven Bids

Yahoo

time38 minutes ago

  • Yahoo

Gold Steady Near Record High as Mideast War Drives Haven Bids

(Bloomberg) -- Gold was steady near a record high as an escalating conflict between Israel and Iran drove investors toward haven assets. Shuttered NY College Has Alumni Fighting Over Its Future As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention Space Do World's Fairs Still Matter? NYC Renters Brace for Price Hikes After Broker-Fee Ban As American Architects Gather in Boston, Retrofits Are All the Rage The precious metal erased gains made earlier on Monday to trade close to $3,430 an ounce, about $70 short of an all-time peak set in April. The two countries continued to hit each other with barrages of missile and drones, with the hostilities pushing up energy prices on the threat to energy infrastructure and transport in the region. The sudden upsurge of geopolitical risk has added more impetus to a rally that's primarily been driven by the threat to global economic growth from President Donald Trump's aggressive tariff agenda. Gold has rallied more than 30% in 2025, with central banks seeking to diversify away from the dollar being another significant driver. 'Prices are still very close to the record, and given the geopolitical situation any further escalation will push them higher,' said John Feeney, an analyst at Guardian Gold Australia. 'Gold has performed very well as a haven recently, and it seems a lot of investors are moving funds out of US bonds and into the metal over the longer term.' A 1.4% jump in the precious metal on Friday came after a two-day gain as weak US inflation and jobs data fueled bets the Federal Reserve will cut interest rates later this year. Lower rates tend to benefit bullion as it doesn't pay any interest. Spot gold dipped 0.2% to $3,427.25 an ounce as of 12:59 p.m. in Singapore. The Bloomberg Dollar Spot Index added 0.1% after dropping 0.8% last week. Silver edged lower, while platinum and palladium advanced. American Mid: Hampton Inn's Good-Enough Formula for World Domination The Spying Scandal Rocking the World of HR Software As Companies Abandon Climate Pledges, Is There a Silver Lining? New Grads Join Worst Entry-Level Job Market in Years US Tariffs Threaten to Derail Vietnam's Historic Industrial Boom ©2025 Bloomberg L.P. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease

Yahoo

time39 minutes ago

  • Yahoo

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease

- Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease - - Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson's disease progression - - Parkinson's disease affects over 10 million people globally and significant unmet need remains - SOUTH SAN FRANCISCO, Calif., June 16, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies. "We are encouraged by the efficacy signals observed across the two Phase II trials and their open-label extensions, combined with the favorable safety and tolerability profile of prasinezumab," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "We also recognize the substantial need for new treatment options, and the totality of data suggest that prasinezumab may have the potential to become the first disease-modifying treatment for people with Parkinson's disease." Multiple endpoints from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson's disease. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, although missed statistical significance. Positive trends towards reduced motor progression at 104 weeks (two years) were observed; these effects appear to be sustained over longer treatment periods based on additional OLE data. The PADOVA study also provided the first biomarker evidence of prasinezumab impacting the underlying disease biology. The PASADENA and PADOVA OLE studies, which are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage Parkinson's disease, are ongoing. About prasinezumab Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease. Data from the Phase IIb PADOVA study suggest the possible clinical benefit of prasinezumab on top of effective symptomatic treatment in early-stage Parkinson's disease. PADOVA investigated prasinezumab in 586 people with early-stage Parkinson's disease, treated for a minimum of 18 months while on stable symptomatic treatment. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01], although the study missed statistical significance (p=0.0657). In a pre-specified analysis, the effect of prasinezumab was more pronounced in the population treated with levodopa (75% of participants), HR=0.79 [0.63-0.99], p=0.0431 (nominal). Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Trends towards reduced motor progression at 104 weeks (two years) were observed, showing 30-40% relative reduction versus placebo across the overall and levodopa-treated populations. Prasinezumab continues to be well tolerated and no new safety signals were observed in the study. The safety database for prasinezumab consists of data from more than 900 Parkinson's disease study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years. Roche/Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated alpha-synuclein, such as prasinezumab, for the treatment of Parkinson's disease. About Parkinson's disease Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disease characterized by the gradual loss of neurons that make dopamine and other nerve cells, and the development of motor and non-motor symptoms that may appear years before diagnosis. Today, Parkinson's disease affects over 10 million people worldwide. The prevalence of Parkinson's disease is increasing, and it has become one of the fastest-growing neurological disorders. Currently, symptomatic treatments that effectively alleviate motor symptoms are available today, having a significant impact on people's quality of life; however, no available symptomatic therapies slow down or stop the clinical progression of Parkinson's disease and the effects wear off over time as the disease progresses. Genentech and Roche are evaluating multiple approaches to slow down disease progression and potentially prevent Parkinson's disease that involve targeting underlying disease processes such as aggregated α-syn production, lysosomal dysfunction and neuroinflammation. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact:Meghan Hindman (650) 467-6800 Advocacy Contact:Jenee Williams (650) 303-2958 Investor Contacts:Loren Kalm (650) 225-3217Bruno Eschli +41 61 687 5284 Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store